Authors : Shivalinga Swamy Salimath, MD Majeed Pasha, Mohan Rao K N, Mahendra M, Sujith Halappa
DOI : 10.18231/2581-4222.2018.0014
Volume : 3
Issue : 2
Year : 0
Page No : 44-49
Background: Lung cancer is the most common cancer and a leading cause of cancer related deaths worldwide. Non-small cell lung cancer (NSCLC) is the most common histological type. The aim of our study was to analyze clinico-pathological profile, treatment outcome and survival of NSCLC patients at a tertiary care centre.
Methodology: A total of 50 patients diagnosed histopathologically to have NSCLC were included in the study. This study was done at J.S.S Medical College and Hospital, Mysore. All patients were prospectively followed up for 6 months. Clinico-pathological profile, treatment outcome, overall survival and performance status were analyzed using Cox Proportional hazard model.
Results: Our study included a total of 50 cases with 44 male (88%) and 6 (12%) female patients with a median age of 65 years (range 42-90 years). 27 cases were adenocarcinomas (54%), 14 Squamous cell carcinomas (28%), 7 poorly differentiated carcinomas (14%) and 2 large cell carcinomas (4%).
Overall survival (OS) among patients receiving treatment was significantly better [HR=2.44(95% CI 1.14-5.22) p=0.02]. Patients treated with Chemotherapy (Carboplatin-Paclitaxel ± Gefitinib) showed significant better survival compared to patients who did not receive chemotherapy [HR=2.73(95% CI 1.03-7.25) p=0.004].
Performance status as measured by both Karnofsky score [HR=5.02(95% CI 1.51-16.67) p=0.008] and ECOG scores [HR=0.26(95% CI 0.09-0.69) p=0.006] were significantly associated with better survival in patients who took treatment.
Conclusions: NSCLC patients who took chemotherapy have a significant better survival and good quality of life.
Keywords: Chemotherapy; NSCLC; Survival.